Family and twin studies have demonstrated that genetic factors account for 50--80% of the inter-individual variation in bone mineral density (BMD) in both women and men \[[@CR1]--[@CR9]\]. Polymorphisms in a number of genes affect the bone phenotype regarding BMD, bone size, or fracture risk \[[@CR10]\]. Only a small part of the overall variation in BMD, however, has been explained by the polymorphisms identified so far.

The transmembrane proteins low-density lipoprotein receptor-related protein 5 (LRP5) and LRP6 are essential in Wnt signaling. They are expressed in many tissues including osteoblasts and have been implicated in the adaptive response of bone to mechanical load \[[@CR11]\]. Located on chromosome 11q12--14, activating mutations in the LRP5 gene are responsible for rare conditions with a "high bone mass phenotype" \[[@CR12], [@CR13]\] as well as autosomal dominant osteopetrosis type 1 \[[@CR14]\], and transgenic mice carrying the LRP5 G171V mutation have increased bone mass and bone biomechanical properties \[[@CR15]\]. Conversely, inactivating mutations are responsible for the osteoporosis pseudoglioma syndrome \[[@CR16]\] and this syndrome is recapitulated by LRP5 inactivation in mice \[[@CR17]\].

In addition to these mutations, a number of polymorphisms have been described in the LRP5 gene (<http://www.ncbi.nlm.nih.gov/SNP>). One of these, the Ala1330Val (rs3736228, exon 18) polymorphism, has been associated with attenuated bone gain in prepubertal boys \[[@CR18]\], decreased BMD in Japanese \[[@CR19]\], American \[[@CR20]\], Australian \[[@CR21]\], and Dutch \[[@CR22]\] women as well as in elderly Dutch men \[[@CR22]\]. It has also been associated with an increased risk of fragility fractures in postmenopausal Australian women \[[@CR21]\] and in elderly Dutch men \[[@CR22]\]. No association, however, was found between this polymorphism and bone loss in elderly men and women \[[@CR22]\]. Similarly, the Val667Met (rs4988321, exon 9) polymorphism was associated with attenuated bone gain in prepubertal boys but not in girls participating in a 1-year longitudinal Swiss study \[[@CR18]\]. In the same study, this polymorphism was also associated with decreased lumbar spine bone mineral content and projected bone area and there was a trend toward lower BMD in the spine \[[@CR18]\]. These associations were mainly driven by men \[[@CR18]\] and in haplotype analysis including Ala1330Val, most of the effect was conferred by the Val667Met polymorphism. Moreover, in a case-control study by Ferrari et al. \[[@CR23]\] on idiopathic osteoporosis in males, both LRP5 polymorphisms significantly increased the odds ratio for osteoporosis. Additionally, Val667Met was associated with low stature in adults of both sexes \[[@CR18]\]. Thus, current evidence suggests that polymorphisms in the LRP5 gene may be involved in the control of peak bone mass and may increase the risk of osteoporosis in males \[[@CR16],[@CR18], [@CR23]\].

In the present study, we investigated the association between the Ala1330Val and Val667Met polymorphisms and peak bone mass in men in a population-based study.

Subjects and Methods {#Sec1}
====================

The Odense Androgen Study (OAS) is a population-based, prospective, observational study on the interrelationship between endocrine status, body composition, muscle function, and bone metabolism in young men. Details on the design and inclusion of participants are reported elsewhere \[[@CR24]\]. In brief, 3,000 men aged 20--30 years were randomly selected from the civil registration database in Fuenen County, Denmark, and invited by mail to participate in the study. These subjects also received a questionnaire regarding smoking, medication, chronic diseases, drug abuse, etc. A total of 2,042 questionnaires were returned, and from these 859 men expressed interest in participation in the clinical part of the study. Nineteen withdrew before an appointment for inclusion was made. Ten men did not meet with the inclusion criteria (Caucasian and age between 20--29 years), and another 3 men gave their notice after the inclusion had stopped. Aside from these latecomers none of the responders were excluded. Of the remaining 827 eligible subjects, 43 did not attend for their appointment and did not wish to reschedule, but informed consent was obtained from 784 men, with dropout from 1 subject. Thus 783 Caucasian men gave written informed consent and were included in the OAS. These participants had similar age, body mass index (BMI), lifestyle, socio-economic status, and educational level as the background population, as evaluated by questionnaires and demographic data (manuscript in preparation). The protocol stipulated that subjects with massive substance or alcohol abuse, malignant disease or severe chronic disease be excluded; however, none of the responders fulfilled any of these criteria. The study was approved by the local Ethics Committee of Fuenen and Vejle Counties (file number 20010198), conducted according to the Helsinki Declaration, and declared in ClinicalTrials.gov: NCT00150163, registered September 6, 2005.

Genotyping {#Sec2}
----------

DNA was isolated from whole blood samples using QIAamp DNA Blood Midi kits (Qiagen, Valencia, CA, USA).

The Ala1330Val polymorphism was analyzed using Taqman primers and probes that were designed using Primer Express software (Applied Biosystems):Sense: 5′-GACGGCGAGGCAGACTGT-3′Antisense: 5′-GCAGGGCCAGGGTCTTG-3′C probe: 5′-FAM-TCAAAGTCCGCCTCGT-NFQ-3′T probe: 5′-VIC-CACAGTCCACCTCGTC-NFQ-3′The real-time analysis was performed using the ABI PRISM 7700 Sequence Detection System. To validate the method, approximately 10% of the samples were repeated and in total 17 samples---at least 5 of each genotype---were sequenced.

The Val667Met polymorphism was analyzed using fluorescence polarization as described previously \[[@CR25]\], using AcycloPrime-FP SNP Detection kits (Perkin Elmer Life Sciences, Boston, MA, USA). PCR fragments containing the polymorphisms were generated using standard conditions with the following PCR primers:Sense: 5-gccTTcTTggTcTTcAccAg-3′Antisense: 5′-cTTTgAggcAggAAcAgAgg-3′Enzymatic clean-up and subsequent AcycloPrime-FP reaction with SNP primer (sense 5′-ccTcgAgAccAATAAcAAcgAc-3′) were performed according to the instructions of the kit manufacturer. Fluorescence polarization was read in a Wallac Victor multilabel plate reader (Perkin Elmer Life Sciences, Boston, MA, USA). Blank samples and samples with known genotype were included as negative and positive controls, respectively. A total of 10% of all samples were sequenced and genotyping confirmed in all cases.

Anthropometrics and Lifestyle {#Sec3}
-----------------------------

Body weight, body height, sitting height, and arm span were measured. Data regarding exercise habits were collected using a self-administered questionnaire. Non-sedentary lifestyle was defined as participation in any form of regular exercise.

Dual-Energy X-ray Absorptiometry (DXA) {#Sec4}
--------------------------------------

BMD of the lumbar spine, hip, and whole-body was measured using a Hologic 4500 DXA-scanner (Waltham, MA, USA). The coefficient of variation (CV) for BMD is 1.5%, 1.5%, and 0.7% in the lumbar spine, total hip, and whole body, respectively. Lean body mass (LBM) and fat mass was obtained from the whole-body scans.

Biochemistry {#Sec5}
------------

Serum samples were drawn after an overnight fast between 08.00 and 10.00 hours and stored for later analyses at −80°C. Serum concentrations of osteocalcin were measured by a luminoimmunoassay (BRAHMS Diagnostica, Berlin, Germany) with an intra-assay and inter-assay CV of 5% and 8%, respectively.

Serum levels of type 1 collagen C-terminal telopeptide (1CTP) were measured using radioimmunoassay (RIA) (Orion Diagnostica, Espoo, Finland) with an intra-assay and inter-assay CV of 4% and 6%, respectively. Bone-specific alkaline phosphatase (bone-AP) concentration in serum was determined enzymatically after monoclonal antibody capture (Metra Biosystems, Mountain View, CA, USA). The intra-assay CV was 2% and the inter-assay CV 12% for this analysis. Serum levels of 25-OH-vitamin D were measured using a competitive radioimmunoassay (DiaSorin, Stillwater, MN, USA) with an intra-assay CV of 6% and an inter-assay CV of 15%. Serum IGF-I was determined in acid--ethanol extracts as described previously \[[@CR26]\]. Intra- and inter-assay variation averaged less than 5% and less than 10%, respectively.

Statistics {#Sec6}
----------

Data are reported as the mean ± SD, median (range), or median \[95% CI\], as appropriate. BMD values are shown in absolute values. Regarding the allele dose-analyses, BMD values were transformed to Z-scores using the SD observed in our population. Hardy-Weinberg equilibrium was checked using chi-square analysis. Linkage disequilibrium (*D*') between polymorphisms was evaluated by using GOLD software \[[@CR27]\]. Haplotype analysis was undertaken using FAMHAP software for constructing haplotypes \[[@CR28]\]. Comparisons between groups were performed using one-way ANOVA, unpaired *t*-test or similar nonparametric tests. Associations between parameters were analyzed using Pearson's regression analysis and multiple linear regression analysis. Dichotomies were tested using the chi-square test. A *p* value of less than 0.05 was considered significant. Statistical analyses were performed using SPSS 11.5 and SPSS 12.0.

Results {#Sec7}
=======

Genotype Frequencies {#Sec8}
--------------------

For the Ala1330Val polymorphism, the CC genotype was found in 589 (75.6%), the CT genotype in 170 (21.8%), and the TT genotype in 20 (2.6%), respectively (Table [1](#Tab1){ref-type="table"}) allele frequencies of 0.87 and 0.13 for the C- and T-alleles, respectively. Table 1Covariates, BMD, and lifestyle (sedentary/non-sedentary) by LRP5 genotypes (Ala1330Val and Val667Met polymorphisms)PolymorphismsAla1330ValVal667MetCCCTTT*p* values (ANOVA)GGGAAA*p* values (ANOVA)*n*58917020--699764--Age (years)25.5 ± 2.825.3 ± 2.825.9 ± 2.7NS25.5 ± 2.825.3 ± 2.627.0 ± 1.8NSBody height (cm)181.7 ± 6.8181.5 ± 6.1182.8 ± 7.7NS181.7 ± 6.8181.3 ± 5.6190.7 ± 6.30.02Arm span (cm)183.4 ± 8.2183.1 ± 7.0185.4 ± 8.9NS183.3 ± 8.0182.6 ± 6.9193.5 ± 6.80.04Body weight (kg)81.9 ± 11.881.1 ± 12.485.9 ± 16.7NS81.7 ± 12.182.2 ± 12.990.4 ± 12.2NSBody mass index (kg/m^2^)24.8 ± 3.324.6 ± 3.725.6 ± 4.1NS24.8 ± 3.325.1 ± 4.324.8 ± 1.8NSTotal fat mass (kg)14.9 ± 6.214.9 ± 7.317.7 ± 8.5NS15.3 ± 6.215.1 ± 6.717.9 ± 7.9NSLean body mass (kg)64.0 ± 7.363.3 ± 6.865.3 ± 9.0NS64.7 ± 6.964.4 ± 6.070.4 ± 7.0NSUnits alcohol/week (*n*)11.4 ± 10.210.7 ± 8.612.3 ± 8.7NS11.0 ± 9.410.8 ± 8.16.5 ± 7.3NSCigarettes/day (*n*)0 \[0--45\]0 \[0--35\]0 \[0--25\]NS0 \[0--35\]0 \[0--30\]0 \[0--1\]NSSerum 25-OH-D~3~ (nmol/l)65.1 ± 27.964.2 ± 26.967.9 ± 28.6NS65.2 ± 27.563.0 ± 29.160.0 ± 25.4NSSerum IGF-I (μg/l)199.9 ± 52.8202.4 ± 50.3191.0 ± 36.1NS27.6 ± 7.525.5 ± 6.627.3 ± 7.8NSSerum osteocalcin (mmol/l)3.0 ± 1.13.1 ± 1.33.0 ± 1.0NS3.1 ± 1.22.8 ± 1.02.3 ± 0.5NSSerum 1CTP (μg/l)5.0 ± 1.44.9 ± 1,55.1 ± 1.3NS5.0 ± 1.44.9 ± 1.44.9 ± 0.9NSBone-AP (U/l)26. 6 ± 8.128.4 ± 10.026.7 ± 8.3NS26.7 ± 8.225.8 ± 7.033.4 ± 16.4NSBMD~spine~ (g/cm^2^)1.08 ± 0.121.07 ± 0.171.05 ± 0.13NS1.08 ± 0.121.07 ± 0.221.07 ± 0.15NSBMD~hip~ (g/cm^2^)0.95 ± 0.140.94 ± 0.140.94 ± 0.15NS0.95 ± 0.140.96 ± 0.150.84 ± 0.070.03BMD~WB~ (g/cm^2^)1.22 ± 0.10\*1.21 ± 0.091.21 ± 0.11NS1.22 ± 0.101.21 ± 0.111.20 ± 0.08NSSedentary/non-sedentary (*n*)150/44037/1334/16NS171/52818/581/3NSNo significant differences were found between the groups (ANOVA). This was true also if the CT and TT genotypes were pooled (*t*-test). Genotypes were in Hardy-Weinberg equilibrium (Ala1330Val: χ^2^ = 3.2, *p* = 0.07; Val667Met: χ^2^ = 1.48, *p* = 0.22)\**p* = 0.05 comparing the CC genotype with CT + TT pooled; NS, not significant

Similarly, the GG, GA, AA genotypes of the Val667Met polymorphism were found in 699 (89.7%), 76 (9.8%), and 4 (0.5%), respectively. This corresponds to allele frequencies of 0.95 and 0.05 for the G- and A-alleles, respectively.

Both allele distributions were compatible with Hardy-Weinberg equilibrium (χ^2^ = 3.2, *p* = 0.07 and χ^2^ = 1.48, *p* = 0.22). The two polymorphisms were not in complete linkage disequilibrium (*D*' = 0.955, *R*² = 0.33).

Covariates {#Sec9}
----------

Data on covariates in relation to genotypes are shown in Table [1](#Tab1){ref-type="table"}. No significant differences regarding covariates (age, body height, body weight, BMI, sitting height (not shown), total fat mass, lean body mass, alcohol consumption, smoking, serum 25-OH-D~3~, or serum IGF-I) were seen between the genotypes of the two polymorphisms. Regarding the Val667Met genotypes, however, subjects with the AA genotype had significantly increased body height (190.7 ± 6.6 vs. 181.7 ± 6.8 and 181.3 ± 5.6 cm, *p* = 0.02) and arm span (193.5 ± 6.8 vs. 183.3 ± 8.0 and 182.6 ± 6.9 cm, *p* = 0.04).

BMD in Relation to Age {#Sec10}
----------------------

In the spine, no relationship between BMD and age could be detected. Maximum BMD in the total hip was observed around the age of 22 years. In subjects above this age BMD was significantly lower (ANOVA, *p* \< 0.05). In subjects aged 30 years, BMD was 5.5% lower that the observed maximum.

Genotypes in Relation to BMD {#Sec11}
----------------------------

Regarding the Ala1330Val polymorphism, no significant differences between BMD in the spine, hip, or whole body were found between subjects with the CC, CT, and TT genotypes. When the CT and TT genotypes were pooled, whole-body BMD was significantly lower in the CT + TT compared with the CC genotype (1.21 ± 0.10 vs. 1.22 ± 0.10, *p* = 0.05).

Regarding the Val 667Met polymorphism, a significant difference in hip BMD was observed, since subjects with the AA genotype had lower BMD (0.84 ± 0.07 vs. 0.95 ± 0.14 and 0.96 ± 0.15, p = 0.03).

Table [1](#Tab1){ref-type="table"} also shows the distribution of genotypes in relation to sedentary/non-sedentary lifestyle, but no significant difference in lifestyle was found between any of the genotypes.

Table [2](#Tab2){ref-type="table"} shows the gene-dose effect on BMD expressed as the change in Z-score of each copy of the T- or A-allele, respectively. The analysis was performed both with and without adjustment for BMI, smoking (0/1), any continuous medication (0/1), and serum 25-OH-D~3~ in the overall study population (multiple regression analysis). Regarding the Ala1330Val polymorphism, whole-body BMD tended to decrease with each copy of the T-allele (*p* = 0.07) in the overall study population (*n* = 779). No significant association between number of T-alleles and BMD at the other skeletal sites was found. Regarding the Val667Met polymorphism, no significant gene-dose effect could be demonstrated in the overall population. Table 2Multiple regression analysis determining the change in BMD Z-score for each copy of the T- or A-allelePolymorphismAla1330ValVal667MetZ-scoreUnadjustedAdjusted^a^UnadjustedAdjusted^a^**Total population (*n* = 779)**BMD~spine~−0.11 (−0.29; 0.06)^NS^−0.10 (−0.27; 0.06)^NS^−0.044 (−0.28; 0.19)^NS^−0.054 (−0.27; 0.16)^NS^BMD~hip~−0.03 (−0.20; 0.11)^NS^−0.02 (−0.17; 0.11)^NS^0.018 (−0.20; 0.23)^NS^0.002 (−0.22; 0.21)^NS^BMD~WB~−0.13 (−0.27; 0.11)^*p* = 0.07^−0.12 (−0.25; 0.01)^*p* = 0.07^−0.085 (−0.30; 0.13)^NS^−0.11 (−0.33; 0.10)^NS^**Non-sedentary (*n* = 589)**BMD~spine~−0.21 (−0.40; −0.03)^*p* = 0.02^−0.20 (−0.37; −0.02)^*p* = 0.01^−0.26 (−0.51; −0.01)^*p* = 0.04^−0.23 (−0.46; −0.002)^*p* = 0.048^BMD~hip~−0.08 (−0.26; 0.09)^NS^−0.06 (−0.22; 0.10)^NS^−0.08 (−0.33; 017)^NS^−0.07 (−0.32; 0.19)^NS^BMD~WB~−0.17 (−0.33; −0.01)^*p* = 0.04^−0.15 (−0.30; 0.01)^*p* = 0.07^−0.17 (−0.41; 0.08)^NS^−0.18 (−0.44; 0.07)^NS^Data are shown as mean effect and 95% confidence interval. Z-scores were derived from the study population itself^a^Adjusted for BMI (ln-transformed), lean body mass (ln-transformed), smoking (0/1), any continuous medication (0/1), and serum 25-OH-D~3~

When analysis was restricted to non-sedentary men (*n* = 589), however, a significant correlation between the number of T-alleles at the Ala1330Val polymorphism and BMD in the spine was found in both the unadjusted (−0.21 \[95% CI: −0.40; −0.03\], *p* = 0.02) (Fig. [1](#Fig1){ref-type="fig"}) and adjusted analysis (−0.20 \[95% CI: −0.37; −0.02\], *p* = 0.01) (Table [2](#Tab2){ref-type="table"}). Similarly, each copy of the A-allele in the Val667Met polymorphism decreased the lumbar spine BMD in unadjusted (−0.26 \[95% CI: −0.51; −0.01\], *p* = 0.04) and adjusted (−0.23 \[95% CI: −0.46; −0.002\], *p* = 0.048) analysis. Fig. 1BMD of the lumbar spine, total hip, and whole body in relation to the genotype regarding the Ala1330Val (upper panel) and the Val667Met (lower panel) polymorphisms in the LRP5 gene. Participants with a non-sedentary (left) and sedentary lifestyle (right) are displayed. Data are shown as the mean ± SE. ^(\*)^*p* \< 0.10, \**p* \< 0.05

Genotypes in Relation to Bone Markers {#Sec12}
-------------------------------------

No significant differences were observed between genotypes of the Ala1330Val or Val667Met polymorphisms regarding bone markers (Table [1](#Tab1){ref-type="table"}).

Haplotype Analysis {#Sec13}
------------------

The effect of haplotypes of the Ala1330Val and Val667Met polymorphisms on BMD adjusted for BMI, lean body mass, smoking, drugs, and vitamin D are shown in Table [3](#Tab3){ref-type="table"}. No significant association between BMD and haplotypes was found. This was also the case when sedentary and non-sedentary men were analyzed separately (not shown). Table 3The effect of haplotypes of Ala1330Val and Val667Met polymorphisms on BMD adjusted for BMI, lean body mass, smoking, drugs, and vitamin DHaplotypesAla1330ValCTVal667MetGAGA*pn*1331312981BMD~spine~ (g/cm^2^)0.008 ± 0.96−0.42 ± 0.65−0.09 ± 0.90−0.04 ± 1.60NSBMD~hip~ (g/cm^2^)−0.002 ± 1.010.97 ± 1.48−0.0005 ± 0.95−0.04 ± 1.0NSBMD~WB~ (g/cm^2^)0.02 ± 1.010.70 ± 0.59−0.10 ± 0.87−0.14 ± 1.04NSData are shown as the mean ± SD. No significant associations between BMD and haplotypes were found when sedentary and non-sedentary men were analyzed separately (not shown)

Discussion {#Sec14}
==========

We found a significant association between the Ala1330Val and the Val667Met polymorphisms in the LRP5 gene and BMD in young men, especially when physical activity was taken into account as confounder. This finding supports a number of recent papers reporting significant associations between polymorphisms in this gene and BMD \[[@CR18], [@CR19], [@CR21], [@CR22]\]. Some of these studies involved or were restricted to men \[[@CR18], [@CR22], [@CR29], [@CR30]\]. Moreover, Ferrari et al. \[[@CR18]\] suggested that the polymorphisms in the LRP5 gene are associated with bone gain in prepubertal boys. Only one study \[[@CR25]\] failed to demonstrate an association between variations in the LRP5 gene and BMD, but most likely this is due to their restricted sample size (*n* = 219).

Major disruption of the LRP5 gene (homozygous nonsense or frame-shift mutations) resulting in loss-of-function has been demonstrated to be responsible for the osteoporosis pseudoglioma syndrome \[[@CR16]\]. Conversely, a number of dominantly inherited gain-of-function mutations result in high bone mass phenotypes \[[@CR12]--[@CR14]\] and autosomal dominant osteopetrosis type 1 \[[@CR14]\]. Minor changes in this gene, i.e., frequently occurring polymorphisms, may also be of importance in the regulation of bone mass as suggested by the association studies mentioned above. Further support comes from mapping a quantitative trait locus for BMD to chromosome 11q12--13 in some \[[@CR31], [@CR32]\] but not all studies \[[@CR7], [@CR33], [@CR34]\]. In a case-control study comprising 78 men with idiopathic osteoporosis and 86 controls, Ferrari et al. \[[@CR23]\] found that Ala1330Val and Val667Met conferred an odds ratio for osteoporosis of 2.98 (95% CI: 1.03--8.81) and 3.27 (95% CI: 1.43--7.44), respectively. Also, a single prospective study \[[@CR21]\] comprising 1,301 elderly Australian women demonstrated that the c.3357A \> G (rs556442) polymorphism was associated with decreased BMD and increased incidence of fractures. This polymorphism located in exon 15 is synonymous but was found to be in linkage disequilibrium with Ala1330Val \[[@CR21]\]. Similarly, Mizuguchi et al. \[[@CR19]\] found a linkage equilibrium block comprising exons 7 to 18. In our study, no significant effect of Ala1330Val or Val667Met on BMD was found apart from the ANOVA analysis which suggested that the AA genotype at Val667Met was associated with low BMD of the hip and increased body height. The number of participants with this genotype, however, was low (*n* = 4) and we found no significant gene-dose effect to back this finding. In non-sedentary subjects, however, we found a significant association between Ala1330Val genotype and the Val667Met and Z-score BMD in the spine both in unadjusted analysis and when adjusted for BMI, smoking, continuous medication, and serum levels of 25-OH-D~3~. Further, we observed an association between Ala1330Val and whole-body BMD in the unadjusted analysis. This interaction between lifestyle (sedentary/non-sedentary), LRP5 genotype, and BMD has not previously been reported. Such an association is fully in line with the proposed role of LRP5 as a player in adapting bone to weight-bearing. LRP5 acts as a co-receptor for Wnt proteins and is expressed in the osteoblast and a number of other cell types. The Ala1330Val (exon 18) polymorphism results in a substitution of alanine with the chemically similar valine. No functional studies have been performed on this polymorphism; however, the polymorphism is located within the second LDL-repeat of LRP5 \[[@CR22]\] and this region is involved in the ligand binding of the LDL-receptor \[[@CR35]\]. Also, preliminary results have shown that drugs that inhibit Dkk binding to LRP5 increase bone formation in vitro \[[@CR36]\] and LRP5 seems to be involved in the adaptive response of bone to mechanical load and may be partly responsible for the "mechanostat" \[[@CR11]\]. It is presently unclear why association between the Ala1330Val and Val667Met genotypes and BMD was found only in the spine and not in the hip in the non-sedentary group. Differences between the skeletal sites regarding loading pattern (compression vs. bending) and bone architecture (trabecular vs. cortical) may be important.

In our study, the numbers of T-alleles and A-alleles of the Ala1330Val and Val667Met polymorphisms, respectively, were associated with a decrease in BMD of the lumbar spine of 0.2 SD in the non-sedentary participants (i.e., approximately 2.5%). Previous studies have assessed this impact to be from 1% \[[@CR20]\] to 15% \[[@CR18]\] in women and men and women, respectively. While a number of genes have been associated with bone mass in women (e.g., PTH \[[@CR37]\], alpha-1 chain of type 1 collagen \[[@CR10]\], vitamin D receptor \[[@CR38]\], transforming growth factor beta-1 \[[@CR39]\], interleukin-6 \[[@CR40]\], and osteoprotegerin \[[@CR41]\]), only a few genes have been shown to be associated with peak bone mass in men. We have previously reported that the MTHFR gene is associated with peak bone mass in the same series of men as reported here \[[@CR42]\]. Each of these polymorphisms including the LRP5 gene only accounts for a fraction of the variability in BMD; however, the 2.5% impact suggested by our study is not trivial.

We found no association between either projected bone area at the spine or hip, or body weight and any of the polymorphisms; however, our data demonstrated a significant impact of the AA genotype of the Val667Met polymorphism and body height as previously reported by Ferrari et al. \[[@CR18]\] and Koay et al. \[[@CR29]\]. In our study, the number of subjects with the AA genotype was, however, very low (*n* = 4). Thus, this finding clearly needs confirmation in other study designs.

The allele frequencies found in our study corresponded closely to those reported in Dutch, Australian, Japanese, and Korean populations \[[@CR19], [@CR21], [@CR22], [@CR30]\].

Our study has some limitations. We only tested two polymorphisms in the LRP5 gene. We cannot, therefore, rule out the possibility that the associations found in our study could be due to other polymorphisms in the LRP5 gene or even in neighboring genes in linkage with the polymorphisms tested. Indeed, Bollerslev et al. \[[@CR21]\] found that several of the polymorphisms in the LRP5 gene were in linkage disequilibrium with each other in Australian women. In our study, haplotype analyses were negative. This might be due to the limited number of participants. Testing large arrays of polymorphisms or haplotypes in relation to many outcome variables (i.e., bone mass at several skeletal sites), however, carry an increased risk of detecting spurious associations. Also, our study had a limited size. Given the observed genotype frequency and BMD values, our study had the power to detect differences in BMDof the spine between CC and CT + TT of 0.037 g/cm^2^ (alpha = 0.05 and beta = 0.80). Similarly, our study had the power to detect differences of 0.070 g/cm^2^ between GG and GA + AA in the overall analysis.

Our study also has several strengths. First, it was population-based. In contrast to most similar studies \[[@CR18], [@CR20]\] that recruited participants by advertisements, we recruited our participants by direct mailing on the basis of the National Personal Registry that includes all Danish citizens. This enabled us to account meticulously for the recruitment of our participants. Thus, our sample was not skewed with respect to key socio-economic parameters \[[@CR24]\]. Second, our population had a relatively homogeneous genetic background both due to a small influx to our population and since participants with a first- or second-generation immigrant background were excluded on the basis on data from our national registry. Third, we selected young men aged 20--30 years since these were expected to have reached their peak bone mass. This was confirmed by our data demonstrating an infinitesimal decrease in BMD by age. Moreover, very few were afflicted with chronic diseases or had long-term exposure of environmental factors that may affect bone mass.

We conclude that the Ala1330Val (exon 18) and Val667Met (exon 9) polymorphisms of the LRP5 gene are significantly associated with lumbar spine peak bone mass in physically active men, potentially accounting for 2.5% of BMD in the spine. This gene-environment interaction provides support for LRP5 as a mediator of load-induced bone formation and suggests that this gene is involved in the pathogenesis of osteoporosis in men.
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